Merck & Co., Inc. (MRK)’s Late-Stage Breakdown

Page 1 of 2

Merck & Co., Inc. (NYSE:MRK)The Food and Drug Administration cancelled an advisory meeting planned for Merck & Co., Inc. (NYSE:MRK)’s post-surgery drug sugammadex. It’s another blow to Merck & Co., Inc. (NYSE:MRK) as investors pay close attention to the beleaguered R&D department now turned over to Roger Perlmutter.

Merck highlighted its top five late-stage projects during the full-year 2011 conference call last February: sugammadex, insomnia treatment suvorexant, HPV vaccine V503, osteoporosis drug odanacatib, and cholesterol drug Tredaptive. All of these drugs have since encountered major problems, and investors are nervous.

Merck & Co., Inc. (NYSE:MRK) has spent $8 billion a year for research and development, but currently has little to show for it. Can the newly returned Perlmutter rescue Merck’s R&D?

Sugammadex hits a bump

Sugammadex is meant to reverse the after-effects of muscle relaxants administered during surgery. If approved, sugammadex would become a first-in-class selective relaxant binding agent, or SRBA. But the drug has had Food and Drug Administration issues since its first new drug application was filed in 2008.

While an early advisory panel had recommended the drug, the FDA issued a “not-approvable” action letter due to allergic reaction concerns. The resubmitted NDA was accepted earlier this year before the panel was cancelled this week. A panel cancellation doesn’t immediately equal the failure of the drug.

But the cancellation serves as one last potential setback for the top five drugs that Merck & Co., Inc. (NYSE:MRK) touted as its late-stage future. Let’s look at what happened to the other four.

Faltering four

The highly anticipated insomnia drug suvorexant recently received a complete response letter centered around dosing. The FDA found that Merck & Co., Inc. (NYSE:MRK)’s suggested 30 to 40 mg dosage was not supported by enough safety data to warrant approval. A low dose of 10 mg was recommended for most patients, but 5 mg was recommended for those taking certain medications that could cause a drug interaction.

Merck said that additional safety or efficacy trials aren’t needed for the 10 mg dose but will require a manufacturing study. The FDA could require additional trials for the 5 mg dosage. Merck’s currently in talks with the FDA to determine the next step for suvorexant.

HPV vaccine V503 hasn’t hit a regulatory roadblock, but it could prove unnecessary. V503 is meant to back up Merck’s market-dominating Gardasil vaccine while offering protection from an additional six genotypes of the disease. But there’s reason to believe that those extra genotypes don’t need to be covered, which would make V503 redundant at best.

Merck & Co., Inc. (NYSE:MRK) announced in the fourth quarter 2012 report that osteoporosis drug odanacatib required some additional safety and efficacy trial from an extension study. That meant pushing back the regulatory filing from the first half of this year to some time in 2014. Merck remained mum on exactly why it was necessary to gather more information.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!